Alaproclate: a pharmacokinetic and biochemical study in patients with dementia of Alzheimer type.

Abstract

Alaproclate, a specific inhibitor of neuronal serotonin re-uptake, was given to 12 patients with dementia of Alzheimer type. The drug was rapidly absorbed and an elimination half-life of 7.1 +/- 0.9 h (+/- SD, n = 8) was calculated. Plasma protein binding for alaproclate was 82 +/- 1%. Two weeks of repeated administration produced plasma concentrations of alaproclate similar to those predicted from a single dose. The pharmacological effect of the drug was demonstrated by an inhibition of serotonin uptake in the patients' platelets and a reduction of the serotonin concentration in blood. Global rating of clinical efficacy showed a positive effect of alaproclate in five of the patients, mainly regarding emotional functions.

• Authors: I Bergman, G Bråne, C G Gottfries, K G Jostell, I Karlsson, L Svennerholm
• Journal: Psychopharmacology (Psychopharmacology (Berl)) Vol. 80 Issue 3 Pg. 279-83 ( 1983) ISSN: 0033-3158 [Print] Germany
• PMID: 6412274 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Serotonin
• alaproclate
• Alanine

Topics

• Aged
• Alanine (analogs & derivatives, blood, therapeutic use)
• Alzheimer Disease (blood, drug therapy)
• Dementia (blood, drug therapy)
• Female
• Humans
• Kinetics
• Male
• Serotonin (blood)